CASI Pharmaceuticals (CASI) Competitors

CASI Pharmaceuticals (NASDAQ:CASI) and Lexaria Bioscience (NASDAQ:LEXX) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, profitability, valuation, community ranking, risk, earnings, media sentiment, institutional ownership and dividends.

Is CASI or LEXX more profitable?

Lexaria Bioscience has a net margin of 0.00% compared to CASI Pharmaceuticals' net margin of -79.30%. CASI Pharmaceuticals' return on equity of -77.55% beat Lexaria Bioscience's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
CASI Pharmaceuticals	-79.30%	-77.55%	-30.64%
Lexaria Bioscience	N/A	-133.97%	-118.89%

Does the media prefer CASI or LEXX?

In the previous week, Lexaria Bioscience had 2 more articles in the media than CASI Pharmaceuticals. MarketBeat recorded 2 mentions for Lexaria Bioscience and 0 mentions for CASI Pharmaceuticals. Lexaria Bioscience's average media sentiment score of 0.32 beat CASI Pharmaceuticals' score of 0.00 indicating that Lexaria Bioscience is being referred to more favorably in the news media.

Company	Overall Sentiment
CASI Pharmaceuticals	Neutral
Lexaria Bioscience	Neutral

Do analysts prefer CASI or LEXX?

CASI Pharmaceuticals currently has a consensus target price of $12.00, suggesting a potential upside of 433.33%. Lexaria Bioscience has a consensus target price of $12.00, suggesting a potential upside of 445.45%. Given Lexaria Bioscience's higher possible upside, analysts clearly believe Lexaria Bioscience is more favorable than CASI Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CASI Pharmaceuticals	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00
Lexaria Bioscience	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00

Which has higher valuation and earnings, CASI or LEXX?

Lexaria Bioscience has lower revenue, but higher earnings than CASI Pharmaceuticals. Lexaria Bioscience is trading at a lower price-to-earnings ratio than CASI Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CASI Pharmaceuticals	$33.88M	0.89	-$26.94M	-$2.02	-1.11
Lexaria Bioscience	$230K	123.30	-$6.66M	-$0.68	-3.24

Does the MarketBeat Community prefer CASI or LEXX?

CASI Pharmaceuticals received 197 more outperform votes than Lexaria Bioscience when rated by MarketBeat users. However, 100.00% of users gave Lexaria Bioscience an outperform vote while only 51.69% of users gave CASI Pharmaceuticals an outperform vote.

Company	Underperform	Outperform
CASI Pharmaceuticals	Outperform Votes 199 51.69%	Underperform Votes 186 48.31%
Lexaria Bioscience	Outperform Votes 2 100.00%	Underperform Votes No Votes

Do institutionals and insiders believe in CASI or LEXX?

22.2% of CASI Pharmaceuticals shares are owned by institutional investors. Comparatively, 13.1% of Lexaria Bioscience shares are owned by institutional investors. 21.2% of CASI Pharmaceuticals shares are owned by company insiders. Comparatively, 7.6% of Lexaria Bioscience shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Summary

Lexaria Bioscience beats CASI Pharmaceuticals on 8 of the 15 factors compared between the two stocks.